Navigation Links
Epigenetic regulation by the MMB/dREAM complex
Date:3/5/2008

In the March 1 issue of G&D, Dr. Joseph Lipsick (Stanford University) and colleagues demonstrate that proteins encoded by the Myb oncogene and the RB tumor suppressor gene function together in the Drosophila MMB/dREAM complex to epigenetically regulate mitotic cell cycle progression.

Drosophila MMB/dREAM includes proteins encoded by the Myb oncogene and the RB and Mip130/Lin-9 tumor suppressor genes, as well as the E2F2 protein which itself binds to the RB protein. While the complex has been previously shown to regulate progression of cell cycle, this paper is the first demonstration of epigenetic regulation of gene expression by Myb and E2F2-RB via the MMB/dREAM complex.

Dr. Lipsick and colleagues found that Myb and E2F2-RB epigenetically regulate expression of the Polo kinase, a key component of cell cycle progression. Using a GFP-Polo reporter gene construct, the researchers were able to monitor Polo gene expression at the level of a single-cell in Drosophila larval imaginal wing discs. They found that flies deficient in both Myb and E2F2 or both Myb and Mip130 displayed variegated patterns of GFP-Polo expression in the same tissue. Furthermore, these patterns of expression were stably inherited through successive rounds of cell division.

Our studies imply that disruptions of the Myb and RB pathways that occur in most human cancers are likely to cause similar epigenetic changes in gene expression. The use of the model organism Drosophila was key to our work because of the powerful experimental tools, the absence of genetic redundancy, and the very well characterized developmental biology in this system.


'/>"/>

Contact: Heather Cosel-Pieper
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1

Related biology news :

1. Environmental epigenetics has potential for preventing and treating disease
2. Einstein researcher receives NIH grant to explore epigenetic regulation of the human genome
3. Human embryonic stem cells remain embryonic because of epigenetic factors
4. UD leads $5.3-million research project on rice epigenetics
5. UD leads $5.3-million research project on rice epigenetics
6. NOAA proposes federal regulations to protect black abalone
7. Stanford researchers publish review of US medical device regulation
8. Physician-scientist urges improved drug regulation to ensure heart safety of non-heart drugs
9. Mechanism for regulation of growth and differentiation of adult muscle stem cells is revealed
10. Regulation of TATA-less promoters
11. The importance of gene regulation for common human disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... MILFORD, Mass. , March 23, 2017 ... leading partner to global in vitro diagnostics ... launch of the industry,s first multiplexed ... inherited disease testing by next-generation sequencing ... materials were developed with input from industry ...
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
(Date:3/23/2017)... , March 23, 2017 According to ... products and derivatives market is fragmented due to the presence of a ... as Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each ... three companies, collectively, held more than 76% of this market in ... As of ...
Breaking Biology Technology: